Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Selection criteria for c-Met-targeted therapies: emerging evidence for biomarkers.

Biomarkers in medicine - 1 Feb 2010

Goetsch Liliane, Caussanel Véronique

Abstract excerpt

Extensive development of targeted therapies emphasize the critical need for biomarkers and major efforts have been engaged to identify screening, prognostic, stratification and therapy-monitoring markers. One of the challenges in translating preclinical studies into effective clinical therapies remains the accurate identification of a responsive subsets of patients. Studies on trastuzumab demonstrated that...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Biomarkers
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Expression

Share to Neoplasms

Share to Phosphorylation

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins c-met

Source

Identifiers

PMID: 20387311
DOI: 10.2217/bmm.09.67

Genes

EGF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Selection criteria for c-Met-targeted therapies: emerging evidence for biomarkers.PMID 20387311Read ↗

The Met receptor tyrosine kinase: a key player in oncogenesis and drug resistance.Semantic proximity Read ↗

Progress and challenges in the identification of biomarkers for EGFR and VEGFR targeting anticancer agents.Semantic proximity Read ↗

Targeting the c-MET signaling pathway for cancer therapySemantic proximity Read ↗

A Comprehensive Outline of Trastuzumab Resistance Biomarkers in HER2 Overexpressing Breast CancerSemantic proximity Read ↗

MET receptor tyrosine kinase as a therapeutic anticancer target.Semantic proximity Read ↗

MET in Lung Cancer: Biomarker Selection Based on Scientific Rationale.Semantic proximity Read ↗

Untying the gordion knot of targeting MET in cancer.Semantic proximity Read ↗

Cancer therapy: can the challenge be MET?Semantic proximity Read ↗

Biomarker development in MET-targeted therapy.Semantic proximity Read ↗

HGF/c-MET pathway in cancer: from molecular characterization to clinical evidenceSemantic proximity Read ↗

Targeting the epidermal growth factor receptor (EGFR)--a new therapeutic option in oncology?Semantic proximity Read ↗

Understanding c-MET signalling in squamous cell carcinoma of the head & neckSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.